Merck & Co. stock rises 1.77% premarket to EUR 133.74
Published on 11/12/2026 at 08:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMorning Drivers For Investors
- Merck & Co. is a US pharmaceutical company with an active medicines pipeline.
- Recent pipeline coverage has focused on efinopegdutide and HIV programs.
Merck & Co. stock traded at EUR 133.74 on Lang & Schwarz at 08:12 CET on Thursday, November 12, 2026, 1.77 percent above the Xetra close of Wednesday, November 11, 2026 at EUR 131.42.
Pipeline And Morning Setup
The premarket indication puts the stock in a stronger position ahead of the regular US session. The move follows recent attention on Merck's clinical pipeline, including positive Phase 2b results for efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage F2 or F3 liver fibrosis.
HIV development programs have also remained in focus in recent coverage, with investors watching the timing and execution of upcoming clinical milestones. For the broader investment case, pipeline progress remains important alongside the company's established pharmaceutical business and the continuing need to offset patent-related pressure through new products and indications.
US equities provide the broader market backdrop for Merck & Co. stock, with the S&P 500 serving as the relevant US benchmark.
